Entrada Therapeutics - TRDA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $21.00
  • Forecasted Upside: 40.19%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$14.98
▲ +0.13 (0.88%)

This chart shows the closing price for TRDA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Entrada Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TRDA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TRDA

Analyst Price Target is $21.00
▲ +40.19% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Entrada Therapeutics in the last 3 months. The average price target is $21.00, with a high forecast of $22.00 and a low forecast of $20.00. The average price target represents a 40.19% upside from the last price of $14.98.

This chart shows the closing price for TRDA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Entrada Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/1/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/28/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/26/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/18/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00Low
1/5/2024OppenheimerInitiated CoverageOutperform$22.00Low
11/27/2023HC WainwrightLower TargetBuy ➝ Buy$25.00 ➝ $20.00Low
9/22/2023HC WainwrightReiterated RatingBuy ➝ Buy$25.00Low
8/9/2023HC WainwrightReiterated RatingBuy ➝ Buy$25.00Low
8/2/2023HC WainwrightReiterated RatingBuy ➝ Buy$25.00Low
4/3/2023HC WainwrightInitiated CoverageBuy$25.00Low
3/22/2023William BlairReiterated RatingOutperformLow
11/8/2022The Goldman Sachs GroupBoost TargetNeutral$13.00 ➝ $18.00Low
10/14/2022William BlairReiterated RatingOutperformLow
8/16/2022The Goldman Sachs GroupBoost TargetNeutral$10.00 ➝ $13.00Low
5/24/2022The Goldman Sachs GroupLower TargetNeutral$22.00 ➝ $10.00High
11/24/2021Evercore ISIInitiated CoverageOutperformHigh
11/23/2021CowenInitiated CoverageOutperformHigh
11/23/2021The Goldman Sachs GroupInitiated CoverageNeutral$29.00High
(Data available from 6/24/2019 forward)

News Sentiment Rating

0.56 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2023
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/27/2023
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2024
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
3/26/2024
  • 7 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2024
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/25/2024
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/24/2024

Current Sentiment

  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Entrada Therapeutics logo
Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $14.98
Low: $14.62
High: $15.50

50 Day Range

MA: $14.39
Low: $11.85
High: $16.45

52 Week Range

Now: $14.98
Low: $10.75
High: $18.44

Volume

52,351 shs

Average Volume

76,940 shs

Market Capitalization

$505.72 million

P/E Ratio

23.78

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Entrada Therapeutics?

The following Wall Street analysts have issued research reports on Entrada Therapeutics in the last twelve months: HC Wainwright, and Oppenheimer Holdings Inc..
View the latest analyst ratings for TRDA.

What is the current price target for Entrada Therapeutics?

2 Wall Street analysts have set twelve-month price targets for Entrada Therapeutics in the last year. Their average twelve-month price target is $21.00, suggesting a possible upside of 40.2%. Oppenheimer Holdings Inc. has the highest price target set, predicting TRDA will reach $22.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $20.00 for Entrada Therapeutics in the next year.
View the latest price targets for TRDA.

What is the current consensus analyst rating for Entrada Therapeutics?

Entrada Therapeutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TRDA will outperform the market and that investors should add to their positions of Entrada Therapeutics.
View the latest ratings for TRDA.

What other companies compete with Entrada Therapeutics?

How do I contact Entrada Therapeutics' investor relations team?

The company's listed phone number is 857-520-9158 and its investor relations email address is [email protected]. The official website for Entrada Therapeutics is www.entradatx.com. Learn More about contacing Entrada Therapeutics investor relations.